Strategies to Screen for Diabetic Retinopathy in Chinese Patients with Newly Diagnosed Type 2 Diabetes

Medicine (United States)

Volumn 94, Issue 45, 2015, Pages e1989-

  Wu, Bin ^a   Li, Jin ^a   Wu, Haixiang ^b  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b FUDAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; CHINA; COMPLICATION; COST BENEFIT ANALYSIS; DIABETIC RETINOPATHY; ECONOMIC MODEL; ECONOMICS; HUMAN; MASS SCREENING; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS;

ADULT; AGED; CHINA; COST-BENEFIT ANALYSIS; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; HUMANS; MASS SCREENING; MIDDLE AGED; MODELS, ECONOMIC;

EID: 84958175249     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000001989     Document Type: Article

References (41)

1. Yang W, Lu J, Weng J, et al. Prevalence of diabetes among men and women in China. N Engl J Med. 2010;362:1090-1101.
2. Cheung N, Mitchell P, Wong TY. Diabetic retinopathy. Lancet. 2010;376:124-136.
3. Mohamed Q, Gillies MC, Wong TY. Management of diabetic retinopathy: a systematic review. JAMA. 2007;298:902-916.
4. Liu L, Wu X, Liu L, et al. Prevalence of diabetic retinopathy in Mainland China: a meta-analysis. PLoS ONE. 2012;7:e45264.
5. Wang FH, Liang YB, Zhang F, et al. Prevalence of diabetic retinopathy in rural China: the Handan Eye Study. Ophthalmology. 2009;116:461-467.
6. Tung TH, Shih HC, Chen SJ, et al. Economic evaluation of screening for diabetic retinopathy among Chinese type 2 diabetics: a community-based study in Kinmen, Taiwan. J Epidemiol. 2008;18:225-233.
7. Jones S, Edwards RT. Diabetic retinopathy screening: a systematic review of the economic evidence. Diabet Med. 2010;27:249-256.
8. Chinese Ophthalmological Society. Retinopathy Working Group: diagnosis and treatment guideline of diabetic retinopathy (2014). Chin J Ophthalmol. 2014;50:851-865.
9. Metcalf CJ, Edmunds WJ, Lessler J. Six challenges in modelling for public health policy. Epidemics. 2015;10:93-96.
10. Karnon J, Stahl J, Brennan A, et al. Modeling using discrete event simulation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-4. Med Decis Making. 2012;32:701-711.
11. Xu Y, Wang L, He J, et al. Prevalence and control of diabetes in Chinese adults. JAMA. 2013;310:948-959.
12. Tu Y, Xu L, Wei WB, et al. Progression of diabetic retinopathy: the Beijing Eye Study. Chin Med J (Engl). 2011;124:3635-3640.
13. Kernick DP. Introduction to health economics for the medical practitioner. Postgrad Med J. 2003;79:147-150.
14. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med. 2006;62:2091-2100.
15. Task Group of the Chinese Guidelines for Pharmacoeconomic Evaluations. China Guidelines for Pharmacoeconomic Evaluations. China J Pharm Econ. 2011;3:7-48.
16. Wu B, Li T, Chen H, et al. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis. Value Health. 2010;13:592-600.
17. Enns EA, Cipriano LE, Simons CT, et al. Identifying best-fitting inputs in health-economic model calibration: a Pareto frontier approach. Med Decis Making. 2015;35:170-182.
18. Kong CY, McMahon PM, Gazelle GS. Calibration of disease simulation model using an engineering approach. Value Health. 2009;12:521-529.
19. Javitt JC, Aiello LP. Cost-effectiveness of detecting and treating diabetic retinopathy. Ann Intern Med. 1996;124 (1 Pt 2):164-169.
20. Vijan S, Hofer TP, Hayward RA. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. JAMA. 2000;283:889-896.
21. Kirkizlar E, Serban N, Sisson JA, et al. Evaluation of telemedicine for screening of diabetic retinopathy in the Veterans Health Administration. Ophthalmology. 2013;120:2604-2610.
22. Klein R, Moss SE, Klein BE, et al. Relation of ocular and systemic factors to survival in diabetes. Arch Intern Med. 1989;149:266-272.
23. Younis N, Broadbent DM, Vora JP, et al. Incidence of sightthreatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: a cohort study. Lancet. 2003;361:195-200.
24. Lee VS, Kingsley RM, Lee ET, et al. The diagnosis of diabetic retinopathy. Ophthalmoscopy versus fundus photography. Ophthalmology. 1993;100:1504-1512.
25. Shi L, Wu H, Dong J, et al. Telemedicine for detecting diabetic retinopathy: a systematic review and meta-analysis. Br J Ophthalmol. 2015;99:823-831.
26. Fransen SR, Leonard-Martin TC, Feuer WJ, et al. Clinical evaluation of patients with diabetic retinopathy: accuracy of the Inoveon diabetic retinopathy-3DT system. Ophthalmology. 2002;109:595-601.
27. Harding SP, Broadbent DM, Neoh C, et al. Sensitivity and specificity of photography and direct ophthalmoscopy in screening for sight threatening eye disease: the Liverpool Diabetic Eye Study. BMJ. 1995;311:1131-1135.
28. Lin DY, Blumenkranz MS, Brothers RJ, et al. The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. Am J Ophthalmol. 2002;134:204-213.
29. Tung TH, Chen SJ, Lee FL, et al. A community-based study for the utility values associated with diabetic retinopathy among type 2 diabetics in Kinmen, Taiwan. Diabetes Res Clin Pract. 2005;68:265-273.
30. Poku E, Brazier J, Carlton J, et al. Health state utilities in patients with diabetic retinopathy, diabetic macular oedema and age-related macular degeneration: a systematic review. BMC Ophthalmol. 2013;13:74.
31. Life tables for WHO Member States. http://www.who.int/gho/countries/chn/en/. Accessed July 18, 2015.
32. National Development and Reform Commission (NDRC). http://en.ndrc.gov.cn/Accessed July 26, 2014.
33. Gould MK, Dembitzer AD, Sanders GD, et al. Low-molecularweight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis. A cost-effectiveness analysis. Ann Intern Med. 1999;130:789-799.
34. List of Chinese Administrative Divisions by GDP Per Capita. http://www.stats.gov.cn/. Accessed March 28, 2015.
35. Eichler HG, Kong SX, Gerth WC, et al. Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? Value Health. 2004;7:518-528.
36. Murray CJ, Evans DB, Acharya A, et al. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9:235-251.
37. Echouffo-Tcheugui JB, Ali MK, Roglic G, et al. Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review. Diabet Med. 2013;30:1272-1292.
38. Drummond M, Barbieri M, Cook J, et al. Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health. 2009;12:409-418.
39. Rachapelle S, Legood R, Alavi Y, et al. The cost-utility of telemedicine to screen for diabetic retinopathy in India. Ophthalmology. 2013;120:566-573.
40. Klein BE. Overview of epidemiologic studies of diabetic retinopathy. Ophthalmic Epidemiol. 2007;14:179-183.
41. Diabetic Retinopathy Clinical Research NetworkWells JA, Glassman AR, et al. . Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema. N Engl J Med. 2015;372:1193-1203.